Chronic Myeloid Leukemia Face-Off: Karmanos Cancer Institute vs Cleveland Clinic

The host of Cancer Network's Face-Off program shown with an introductory slide

EP. 1: Team Introductions: CML Experts From Karmanos Cancer Institute and Cleveland Clinic

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

A panel of experts on chronic myeloid leukemia from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in the disease space.

Jay Yang, MD, an expert on chronic myeloid leukemia, presenting clinical trial data

EP. 2: Ponatinib Dose-Ranging Data in Chronic-Phase CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

Jay Yang, MD, reviews data from the OPTIC trial, a ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia.

EP. 3: Treatment Considerations for Ponatinib in Patients With CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.

Moaath Mustafa Ali, MD, MPH, an expert on chronic myeloid leukemia

EP. 4: Olverembatinib in Patients with Pretreated/Refractory CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Moaath Mustafa Ali, MD, MPH, reviews data on olverembatinib in patients with heavily pretreated/refractory chronic myeloid leukemia.

EP. 5: Potential Role of Olverembatinib in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

The expert panel discusses the potential role of olverembatinib in the chronic myeloid leukemia treatment landscape.

Charles A. Schiffer, MD, an expert on chronic myeloid leukemia

EP. 6: ASCEMBL: Recent Data Updates for Asciminib in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

Charles A. Schiffer, MD, reviews clinical trial data for asciminib in chronic myeloid leukemia and highlights financial toxicity concerns.

EP. 7: Clinical Applications for Asciminib in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

Experts in the field of chronic myeloid leukemia discuss the role of asciminib in the overall treatment landscape.

John Molina, MD, MEd, an expert on chronic myeloid leukemia

EP. 8: OPTIC Trial: 3-Year Data Update in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

John C. Molina, MD, EdM, reviews data from the 3-year update from the OPTIC study, and other experts offer their impressions.

EP. 9: Treatment Updates and Key Highlights in Multiple Myeloma and CML

ByONCOLOGY Staff

November 13th 2023

Karmanos Cancer Institute and Cleveland Clinic gave presentations regarding treatment of multiple myeloma and chronic myeloid leukemia in the latest Face Off.

Chronic Myeloid Leukemia Face-Off: Karmanos Cancer Institute vs Cleveland Clinic

EP. 1: Team Introductions: CML Experts From Karmanos Cancer Institute and Cleveland Clinic

EP. 2: Ponatinib Dose-Ranging Data in Chronic-Phase CML

EP. 3: Treatment Considerations for Ponatinib in Patients With CML

EP. 4: Olverembatinib in Patients with Pretreated/Refractory CML

EP. 5: Potential Role of Olverembatinib in CML

EP. 6: ASCEMBL: Recent Data Updates for Asciminib in CML

EP. 7: Clinical Applications for Asciminib in CML

EP. 8: OPTIC Trial: 3-Year Data Update in CML

EP. 9: Treatment Updates and Key Highlights in Multiple Myeloma and CML

Trending on CancerNetwork

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma

Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment

Searching for Synergy in Liver-Dominant Neuroendocrine Tumors

Managing Early Adverse Events With Amivantamab + Lazertinib